Nektar Therapeutics
NKTR58.760USD
+7.690+15.06%
收盘 09/18, 16:00（美东）报价延迟15分钟
731.99M总市值
亏损市盈率 TTM
关于 Nektar Therapeutics 公司
Nektar Therapeutics 是一家临床阶段的生物技术公司。该公司专注于开发治疗自身免疫和慢性炎症疾病中潜在免疫功能障碍的治疗方法。在肿瘤学方面，该公司专注于开发基于靶向生物途径的药物，这些途径可刺激和维持人体的免疫反应以对抗癌症。其主要候选产品 rezpegaldesleukin (REZPEG 或 NKTR-358) 是一种新型调节性 T 细胞刺激剂，目前正在进行两项 2b 期临床试验，一项针对特应性皮炎，一项针对斑秃。其产品线还包括临床前二价肿瘤坏死因子受体 II 型 (TNFR2) 抗体和双特异性项目 NKTR-0165 和 NKTR-0166，以及改良的造血集落刺激因子 (CSF) 蛋白 NKTR-422。该公司还在几项正在进行的临床试验中对 NKTR-255 进行评估，NKTR-255 是一种试验性的 IL-15 受体激动剂，旨在增强免疫系统抗癌的自然能力。
公司简介
公司代码NKTR
公司名称Nektar Therapeutics
上市日期May 03, 1994
CEOMr. Howard W. Robin
员工数量61
证券类型Ordinary Share
年结日May 03
公司地址455 Mission Bay Boulevard South
城市SAN FRANCISCO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编94158
电话18554826587
网址https://www.nektar.com/
公司代码NKTR
上市日期May 03, 1994
CEOMr. Howard W. Robin
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.83K
-32.35%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
15.15K
-12.71%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Sandra A. Gardiner
Ms. Sandra A. Gardiner
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Mark A. Wilson, J.D.
Mr. Mark A. Wilson, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Mr. Corey Davis
Mr. Corey Davis
Managing Director
Managing Director
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.83K
-32.35%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
15.15K
-12.71%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
暂无数据
地区USD
名称
营收
占比
Rest of world
97.05M
98.60%
United States
1.38M
1.40%
业务
地区
暂无数据
股东统计
更新时间: 9月10日 周三
更新时间: 9月10日 周三
持股股东
股东类型
持股股东
持股股东
占比
BVF Partners L.P.
6.71%
The Vanguard Group, Inc.
3.84%
Nantahala Capital Management, LLC
3.73%
Millennium Management LLC
3.41%
AQR Capital Management, LLC
2.25%
其他
80.06%
持股股东
持股股东
占比
BVF Partners L.P.
6.71%
The Vanguard Group, Inc.
3.84%
Nantahala Capital Management, LLC
3.73%
Millennium Management LLC
3.41%
AQR Capital Management, LLC
2.25%
其他
80.06%
股东类型
持股股东
占比
Hedge Fund
22.42%
Investment Advisor
14.24%
Investment Advisor/Hedge Fund
9.72%
Research Firm
1.82%
Individual Investor
0.71%
Family Office
0.23%
Venture Capital
0.08%
Pension Fund
0.01%
其他
50.76%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
342
8.92M
53.56%
-2.95M
2025Q1
408
8.48M
68.15%
-4.47M
2024Q4
427
136.20M
73.84%
-69.28M
2024Q3
442
143.71M
78.07%
-57.20M
2024Q2
458
138.43M
75.38%
-54.08M
2024Q1
477
115.32M
62.79%
-91.21M
2023Q4
499
122.94M
64.45%
-94.24M
2023Q3
522
148.15M
77.94%
-68.45M
2023Q2
531
142.56M
75.34%
-88.27M
2023Q1
545
178.73M
94.47%
-35.40M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
820.65K
4.92%
-1.22K
-0.15%
Mar 31, 2025
Nantahala Capital Management, LLC
519.27K
3.12%
-1.40K
-0.27%
Mar 31, 2025
Millennium Management LLC
932.86K
5.6%
+780.28K
+511.36%
Jun 27, 2025
AQR Capital Management, LLC
242.72K
1.46%
+187.17K
+336.95%
Mar 31, 2025
Acadian Asset Management LLC
486.78K
2.92%
+6.71K
+1.40%
Mar 31, 2025
PRIMECAP Management Company
356.97K
2.14%
-12.39K
-3.35%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
873.88K
5.24%
-15.04K
-1.69%
Mar 31, 2025
TCG Crossover Management, LLC
266.67K
1.6%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.9%
Simplify Health Care ETF
0.84%
Fidelity Enhanced Small Cap ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Schwab U.S. Small-Cap ETF
0.01%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0.9%
Simplify Health Care ETF
占比0.84%
Fidelity Enhanced Small Cap ETF
占比0.04%
Invesco RAFI US 1500 Small-Mid ETF
占比0.03%
Schwab U.S. Small-Cap ETF
占比0.01%
iShares Biotechnology ETF
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
